about
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.Safety and pharmacology of oseltamivir in clinical use.Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacidsA personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?QT Correction: Using an Observed Regression Factor Applicable to a Population Subset.There is no better time than the present: nanotechnology as a disruptive innovation for drug development.Active transport of nitrofurantoin into rat milk.Change in creatinine clearance with advancing age.Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.Can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?Active transport of cimetidine into human milkPharmacokinetics of caffeine and its demethylated metabolites in lactation: predictions of milk to serum concentration ratiosClonazepam and sertraline: absence of drug interaction in a multiple-dose studyReciprocating dialysis tube method: periodic tapping improved in vitro release/dissolution testing of suppositoriesDoes erythromycin have anti-inflammatory effects independent of its antimicrobial action?Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug developmentProposed Strategies for the Integration of Genomics in Primary CareA Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human DiseasesA Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases
P50
Q33956427-F4B8AB84-4890-4A0A-B2B5-0DA04BA9C59FQ35196192-322A8441-633B-44C2-ADF7-1605A08F82A6Q35804050-23B7045D-EEC5-4B5E-A5EC-EBDC43F5CEE8Q38981163-11A924E1-2E02-4080-8278-0C5928B6E7C9Q39837188-FB98D480-D4A2-4252-B244-C6C8848159B1Q43763743-D972E1FD-1C3D-4300-809C-01C847975B1EQ43852118-9F74791C-023C-4BFA-865D-AF130DD9650AQ44181978-4FD08104-34C6-4842-8289-8EEA28844FAEQ44414070-00E9F36F-981F-422F-8356-65677DE548C4Q44544248-6FFBA98F-4CAC-49AE-AA68-7160868AEF4EQ45403737-4E595ABF-2CB6-49F4-8F0A-0E02178FCD83Q46004469-6C475F98-0CA8-4F28-933E-93C90DB1A548Q46107321-B51C72DF-0F9D-4A2C-9EA3-02A4C28335AAQ47913545-CDDCC60C-1500-4E8B-B9F5-E384615B6E1FQ71809399-E8FC192C-2F45-4042-8F39-05C9B07BB43AQ72320804-984EA54E-80C8-4370-8F3A-431643FDF375Q73398402-9E106911-8729-4206-9C12-C19B20438E17Q80063350-1D8600AE-4AF4-4D4D-928C-BBD95D337464Q84831537-838555CC-4B02-491F-8B08-6764CF3C94C2Q87399695-25B22090-F7AC-47D3-A326-5BB4D31A1CFFQ87705320-3B359C15-D873-499C-A5B2-5D93E07EEB01Q89772148-56617BFB-57FA-48ED-860E-4572106E58D3Q91892025-86050A1B-F8C1-42F9-A1A2-F9F6B0FC6812
P50
description
researcher ORCID ID = 0000-0002-6754-6425
@en
name
Charles Oo
@ast
Charles Oo
@en
Charles Oo
@es
Charles Oo
@nl
type
label
Charles Oo
@ast
Charles Oo
@en
Charles Oo
@es
Charles Oo
@nl
prefLabel
Charles Oo
@ast
Charles Oo
@en
Charles Oo
@es
Charles Oo
@nl
P31
P496
0000-0002-6754-6425